<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994808</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121616</org_study_id>
    <secondary_id>NCI-2021-07474</secondary_id>
    <secondary_id>10598</secondary_id>
    <nct_id>NCT04994808</nct_id>
  </id_info>
  <brief_title>Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medexus Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trials studies the effect of treosulfan-based versus clofarabine-based&#xD;
      conditioning regimens before donor hematopoietic stem cell transplant in treating patients&#xD;
      with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.&#xD;
      Chemotherapy drugs, such as treosulfan, fludarabine, and clofarabine, work in different ways&#xD;
      to stop the growth of cancer cells, either by killing the cells, by stopping them from&#xD;
      dividing, or by stopping them from spreading. Giving chemotherapy and total-body irradiation&#xD;
      before a donor hematopoietic stem cell transplant helps kill cancer cells in the body and&#xD;
      helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to&#xD;
      grow. When the healthy stem cells from a donor are infused into a patient, they may help the&#xD;
      patient's bone marrow make more healthy cells and platelets and may help destroy any&#xD;
      remaining cancer cells. This study may help doctors determine whether treosulfan-based or&#xD;
      clofarabine-based conditioning regimen works better before donor hematopoietic stem cell&#xD;
      transplant in treating patients with myelodysplastic syndromes, chronic myelomonocytic&#xD;
      leukemia, or acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients receive treosulfan intravenously (IV) over 2 hours on days -6 to -4 and&#xD;
      fludarabine IV over 30 minutes on days -6 to -2. Patients also undergo total-body irradiation&#xD;
      (TBI) followed by HCT on day 0.&#xD;
&#xD;
      ARM B: Patients receive clofarabine IV over 2 hours on days -6 to -2. Patients also undergo&#xD;
      TBI followed by HCT on day 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>At 6 months after transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-relapse mortality</measure>
    <time_frame>At 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>At 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft versus host disease</measure>
    <time_frame>At 1 year after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm A (treosulfan, fludarabine, TBI, HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treosulfan IV over 2 hours on days -6 to -4 and fludarabine IV over 30 minutes on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (clofarabine, TBI, HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (clofarabine, TBI, HCT)</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (treosulfan, fludarabine, TBI, HCT)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo HCT</description>
    <arm_group_label>Arm A (treosulfan, fludarabine, TBI, HCT)</arm_group_label>
    <arm_group_label>Arm B (clofarabine, TBI, HCT)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Infusion</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
    <other_name>stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm A (treosulfan, fludarabine, TBI, HCT)</arm_group_label>
    <arm_group_label>Arm B (clofarabine, TBI, HCT)</arm_group_label>
    <other_name>SCT_TBI</other_name>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (treosulfan, fludarabine, TBI, HCT)</arm_group_label>
    <other_name>1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-</other_name>
    <other_name>Dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>Trecondi</other_name>
    <other_name>Treosulphan</other_name>
    <other_name>Tresulfon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years and =&lt; 70 years&#xD;
&#xD;
          -  Diagnosis of MDS, CMML, or AML:&#xD;
&#xD;
               -  AML: must have &lt; 5% marrow blasts (by morphology and/or flow cytometry) at the&#xD;
                  time of transplant&#xD;
&#xD;
               -  MDS: must have intermediate, high or very high Revised International Prognostic&#xD;
                  Scoring System (IPSS-R) score; must have &lt; 5% marrow blasts (by morphology and/or&#xD;
                  flow cytometry) at the time of transplant&#xD;
&#xD;
               -  CMML: must have &lt; 5% marrow blasts (by morphology and/or flow cytometry) at the&#xD;
                  time of transplant&#xD;
&#xD;
          -  Karnofsky performance score (KPS) &gt;= 60% on pre-HCT evaluation&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Patients with previous autologous or allogeneic HCT may enroll&#xD;
&#xD;
          -  DONOR: Human leukocyte antigen (HLA)-identical related donors or unrelated donors&#xD;
             matched for HLA-A, B, C, DRB1, and DQB1 as defined by high resolution deoxyribonucleic&#xD;
             acid (DNA) typing; mismatch for only one HLA allele at class I is allowed&#xD;
&#xD;
          -  DONOR: Donors able to undergo peripheral blood stem cell collection. Only granulocyte&#xD;
             colony-stimulating factor (G-CSF) mobilized peripheral blood stem cell (PBSC) will be&#xD;
             permitted as an hematopoietic stem cell (HSC) source on this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of circulating blasts (in the blood) detected by standard pathology for&#xD;
             patients with AML&#xD;
&#xD;
          -  Presence of &gt;= 5% circulating leukemic blasts (in the blood) detected by standard&#xD;
             pathology for patients with MDS and CMML&#xD;
&#xD;
          -  Patients with promyelocytic AML&#xD;
&#xD;
          -  Organ dysfunction&#xD;
&#xD;
               -  Cardiac: Ejection fraction &lt; 35% (or, if unable to obtain ejection fraction,&#xD;
                  shortening fraction of &lt; 26%) or cardiac insufficiency requiring treatment or&#xD;
                  symptomatic coronary artery disease. Patients with a shortening fraction &lt; 26%&#xD;
                  may be enrolled if approved by a cardiologist&#xD;
&#xD;
               -  Pulmonary:&#xD;
&#xD;
                    -  Diffusion capacity of the lung for carbon monoxide (DLCO) &lt; 40%, total lung&#xD;
                       capacity (TLC) &lt; 40%, forced expiratory volume in 1 second (FEV1) &lt; 40%&#xD;
                       and/or receiving supplementary continuous oxygen. When pulmonary function&#xD;
                       test (PFT)s cannot be obtained, the 6-minute walk test (6 minute walk&#xD;
                       functional test [6MWT], also known as exercise oximetry) will be used: Any&#xD;
                       patient with oxygen saturation on room air of &lt; 89% during a 6MWT will be&#xD;
                       excluded&#xD;
&#xD;
                    -  The principal investigator (PI) must approve enrollment of all patients with&#xD;
                       pulmonary nodules&#xD;
&#xD;
               -  Renal: Serum creatinine should be within normal limits as specified by Standard&#xD;
                  Practice guidelines. For subjects with serum creatinine &gt; upper limit of normal,&#xD;
                  a 24-hour creatinine clearance will be performed and should be equal to or more&#xD;
                  than the lower limit of normal&#xD;
&#xD;
               -  Hepatic: Patients with clinical or laboratory evidence of liver disease will be&#xD;
                  evaluated for the cause of liver disease, its clinical severity in terms of liver&#xD;
                  function, and the degree of portal hypertension. Patients will be excluded if&#xD;
                  they are found to have fulminant liver failure, cirrhosis of the liver with&#xD;
                  evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a&#xD;
                  history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable&#xD;
                  hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time,&#xD;
                  ascites related to portal hypertension, bridging fibrosis, bacterial or fungal&#xD;
                  liver abscess, biliary obstruction, chronic viral hepatitis with total serum&#xD;
                  bilirubin &gt; 3 mg/dL, or symptomatic biliary disease&#xD;
&#xD;
          -  With active infectious disease requiring deferral of conditioning, as recommended by&#xD;
             an infectious disease specialist&#xD;
&#xD;
          -  Fungal infections with radiological progression after receipt of amphotericin B or&#xD;
             active triazole for greater than 1 month&#xD;
&#xD;
          -  With human immunodeficiency virus (HIV)-positivity or active infectious hepatitis&#xD;
             because of possible risk of lethal infection when treated with immunosuppressive&#xD;
             therapy&#xD;
&#xD;
          -  With central nervous system (CNS) leukemia at the time of treatment&#xD;
&#xD;
          -  Patients with active non-hematologic malignancies (except non-melanoma skin cancers)&#xD;
             or those with non-hematologic malignancies (except non-melanoma skin cancers) who have&#xD;
             been rendered with no evidence of disease but have a greater than 20% chance of having&#xD;
             disease recurrence within five years. This exclusion does not apply to patients with&#xD;
             non-hematologic malignancies that do not require therapy&#xD;
&#xD;
          -  With life expectancy severely limited by diseases other than malignancy&#xD;
&#xD;
          -  Fertile men and women unwilling to used contraceptive techniques during treatment and&#xD;
             for 12 months following&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  With known hypersensitivity to treosulfan, fludarabine, or clofarabine&#xD;
&#xD;
          -  The use of non-Food and Drug Administration (FDA) approved investigational drugs would&#xD;
             not be allowed within 4 weeks of the initiation of conditioning (day -6 for both arms)&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  DONOR: Donor (or centers) who will exclusively donate marrow&#xD;
&#xD;
          -  DONOR: Donors who are HIV-positive and/or, medical conditions that would result in&#xD;
             increased risk for G-CSF mobilization and harvest of PBSC&#xD;
&#xD;
          -  DONOR: Donors are excluded when preexisting immunoreactivity is identified that would&#xD;
             jeopardize donor hematopoietic cell engraftment. This determination is based on the&#xD;
             standard practice of the individual institution. The recommended procedure for&#xD;
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel&#xD;
             reactive antibody (PRA) screens to class I and class II antigens for all patients&#xD;
             before HCT. If the PRA shows &gt; 10% activity, then flow cytometric or B and T cell&#xD;
             cytotoxic cross matches should be obtained. The donor should be excluded if any of the&#xD;
             cytotoxic cross match assays are positive. For those patients with an HLA Class I&#xD;
             allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be&#xD;
             obtained regardless of the PRA results. A positive anti-donor cytotoxic cross match is&#xD;
             an absolute donor exclusion&#xD;
&#xD;
          -  DONOR: Donor is excluded if a patient is homozygous in the graft-rejection vector&#xD;
             against the donor's mismatched HLA class I allele&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phuong Vo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phuong Vo</last_name>
    <phone>206.667.2749</phone>
    <email>ptvo@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Phuong Vo</last_name>
      <phone>206-667-2749</phone>
      <email>ptvo@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Phuong Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

